Study S002242

Targeting Beta Cell Dysfunction in Longstanding T1D

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03632759
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: EARLY_PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 16
Start: 2018-08-15
Primary completion: 2021-11-09
Lead sponsor: Carla Greenbaum, MD
Conditions: Type 1 Diabetes Mellitus
Interventions: DRUG:Liraglutide; DRUG:Golimumab
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL. [0-to-8 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023591	Testing a new platform to screen disease-modifying therapy in type 1 diabetes. Lord SM, PloS one	2023	Randomized trial	PMID 38096190 DOI	cites ClinicalTrials.gov:NCT03632759; registry reference DERIVED:38096190